Transcat, Inc. announced the acquisition of SCM Metrology and Laboratories S.A. for approximately $13 million in cash, closing on April 9 2026. The deal adds a new regional laboratory network and customer base in Costa Rica, giving Transcat its first operational presence in Latin America.
SCM is a privately held calibration services provider that has operated for more than 20 years and is ISO/IEC 17025‑accredited. The company serves multinational medical‑device and life‑sciences customers from the Coyol Free Trade Zone, a hub that benefits from Costa Rican government incentives.
The transaction aligns with Transcat’s strategy of geographic expansion and portfolio diversification. By adding SCM’s capabilities, Transcat can cross‑sell its Service and Distribution segments, leveraging SCM’s existing relationships to broaden its reach across the Americas and strengthen its position in regulated markets such as life sciences, aerospace, and defense.
Transcat’s 2025 revenue was $278.4 million. The $13 million purchase represents a modest investment relative to its annual top line, underscoring disciplined capital allocation and positioning the company to capture growth in Latin American markets where demand for calibrated instruments is rising.
CEO Jaime Irick said, "The acquisition of SCM represents an important milestone for Transcat as we expand our services and expertise into the Latin American market." The move is expected to strengthen Transcat’s service network and enhance its ability to serve clients across the Americas.
While the article does not report immediate market reaction, the acquisition is likely to be viewed positively by investors seeking exposure to regulated calibration services, given Transcat’s track record of successful integrations such as Martin Calibration and Essco Calibration Laboratory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.